However, with the more recently introduced SGLT2 inhibitors and GLP-1 receptor agonists having shown impressive cardiovascular risk reduction in addition to glycemic control efficacy, these newer agents may also be considered as first-line therapies in patients with pre-existing cardiovascular or renal disease (Garber 2020)
Bake for 1820 minutes, until lightly golden and set
Overall, the combined clinical utility, regulatory support, and expanding patient populations indicate a high-growth trajectory for the GLP-1 analogues market in the coming years
Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR, et al
$149 introductory month
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake